Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.

Pauline Du RusquecClément PalpacuerLoic CampionAnne PatsourisPaule AugereauCarole GourmelonMarie RobertLaurence DumasFolliard CarolineMario CamponeJean-Sébastien Frenel

Published in: Breast cancer research and treatment (2017)

In this heavily pretreated population including everolimus, fulvestrant plus palbociclib provides an mPFS of 5.8 months with the same magnitude of benefit for fulvestrant-pretreated patients.

Keyphrases

metastatic breast cancer
ejection fraction
newly diagnosed
prognostic factors
patient reported outcomes